First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial
Titel:
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial
Auteur:
Zhou, Aiping Shen, Pengfei Li, Juan Qu, Wang Wang, Zengjun Ren, Xiubao Li, Yuan Jiang, Shusuan Li, Gang Zeng, Yu Qin, Weijun Wu, Jin Chen, Peng Zhou, Fangjian Guo, Hongqian Ji, Zhigang Wang, Yongquan He, Zhisong Wu, Jitao Shi, Benkang Liu, Lian Yao, Xudong Ma, Lulin Liu, Ziling Gou, Xin Fu, Bin Wang, Shaogang Jiang, Kui Chong, Tie Tu, Xinhua Zhang, Xu Yu, Dexin Rexiati, Mulati Xue, Xueyi Fei, Jing Wan, Jianghou Jia, Liqun He, Yi Cui, Tongjian Yang, An-Qi Guo, Jun Sheng, Xinan